Predictive factors of methotrexate monotherapy success in patients with rheumatoid arthritis in a national referral center: a cohort study-Reference-Cited by-同舟云学术

Predictive factors of methotrexate monotherapy success in patients with rheumatoid arthritis in a national referral center: a cohort study

Published:2024-09-12 Issue:1 Volume:8 Page:
ISSN:2520-1026
Container-title:BMC Rheumatology
language:en
Short-container-title:BMC Rheumatol

Author:

Hidayat Rudy,Fauzia Fara,Parlindungan Faisal,Wibowo Suryo Anggoro Kusumo,Ariane Anna,Damanik Johanda,Araminta Abirianty Priandani

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s41927-024-00412-8.pdf

Reference35 articles.

1. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis. JAMA. 2018;320(13):1360.

2. Hidayat R, Suryana B, Wijaya L, Ariane A, Hellmi R, Adnan E et al. Diagnosis dan pengelolaan artritis reumatoid. Jakarta: Perhimpunan Reumatologi Indonesia; 2021.

3. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res [Internet]. 2018;6(1):15. https://www.nature.com/articles/s41413-018-0016-9

4. Nam JL, Villeneuve E, Hensor EMA, Conaghan PG, Keen HI, Buch MH, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014;73(1):75–85.

5. Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X, et al. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis. 2017;76(1):96–104.